JP2020502248A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502248A5
JP2020502248A5 JP2019534685A JP2019534685A JP2020502248A5 JP 2020502248 A5 JP2020502248 A5 JP 2020502248A5 JP 2019534685 A JP2019534685 A JP 2019534685A JP 2019534685 A JP2019534685 A JP 2019534685A JP 2020502248 A5 JP2020502248 A5 JP 2020502248A5
Authority
JP
Japan
Prior art keywords
pharmaceutical preparation
preparation according
treating
compound
cerebral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019534685A
Other languages
English (en)
Japanese (ja)
Other versions
JP7117306B2 (ja
JP2020502248A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/031836 external-priority patent/WO2018118109A1/en
Publication of JP2020502248A publication Critical patent/JP2020502248A/ja
Publication of JP2020502248A5 publication Critical patent/JP2020502248A5/ja
Priority to JP2022105969A priority Critical patent/JP7461414B2/ja
Application granted granted Critical
Publication of JP7117306B2 publication Critical patent/JP7117306B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019534685A 2016-12-21 2017-05-09 Rhoキナーゼ阻害剤BA‐1049(R)及びその活性代謝物 Active JP7117306B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022105969A JP7461414B2 (ja) 2016-12-21 2022-06-30 Rhoキナーゼ阻害剤BA‐1049(R)及びその活性代謝物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437181P 2016-12-21 2016-12-21
US62/437,181 2016-12-21
PCT/US2017/031836 WO2018118109A1 (en) 2016-12-21 2017-05-09 Rho kinase inhibitor ba-1049 (r) and active metabolites thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022105969A Division JP7461414B2 (ja) 2016-12-21 2022-06-30 Rhoキナーゼ阻害剤BA‐1049(R)及びその活性代謝物

Publications (3)

Publication Number Publication Date
JP2020502248A JP2020502248A (ja) 2020-01-23
JP2020502248A5 true JP2020502248A5 (https=) 2020-06-18
JP7117306B2 JP7117306B2 (ja) 2022-08-12

Family

ID=62627011

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019534685A Active JP7117306B2 (ja) 2016-12-21 2017-05-09 Rhoキナーゼ阻害剤BA‐1049(R)及びその活性代謝物
JP2022105969A Active JP7461414B2 (ja) 2016-12-21 2022-06-30 Rhoキナーゼ阻害剤BA‐1049(R)及びその活性代謝物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022105969A Active JP7461414B2 (ja) 2016-12-21 2022-06-30 Rhoキナーゼ阻害剤BA‐1049(R)及びその活性代謝物

Country Status (8)

Country Link
EP (2) EP4509138A3 (https=)
JP (2) JP7117306B2 (https=)
DK (1) DK3558314T3 (https=)
ES (1) ES3002432T3 (https=)
FI (1) FI3558314T3 (https=)
PL (1) PL3558314T3 (https=)
PT (1) PT3558314T (https=)
WO (1) WO2018118109A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10106525B2 (en) 2015-01-26 2018-10-23 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
US10857157B2 (en) 2015-01-26 2020-12-08 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors
US11198680B2 (en) 2016-12-21 2021-12-14 BioAxone BioSciences, Inc. Rho kinase inhibitor BA-1049 (R) and active metabolites thereof
EP4509138A3 (en) * 2016-12-21 2025-04-23 BioAxone BioSciences, Inc. Rho kinase inhibitor ba-1049 (r) and active metabolites thereof
US10537567B2 (en) 2017-07-11 2020-01-21 BioAxone BioSciences, Inc. Kinase inhibitors for treatment of disease
JP7664834B2 (ja) * 2018-11-06 2025-04-18 サーベロ・セラピューティクス・エル・エル・シー Rockキナーゼ阻害剤
US12253482B2 (en) 2019-11-01 2025-03-18 Kirin Holdings Kabushiki Kaisha Method for determining structure of substance in multicomponent sample
US20230053333A1 (en) * 2019-11-21 2023-02-23 Kirin Holdings Kabushiki Kaisha Preparation method of crystal structure analysis sample for structural analysis using crystal sponge method
JP7213839B2 (ja) * 2019-11-21 2023-01-27 キリンホールディングス株式会社 結晶スポンジ法による構造解析のための結晶構造解析用試料の調製方法
WO2023060820A1 (zh) * 2021-10-15 2023-04-20 合肥中科普瑞昇生物医药科技有限公司 胃癌原代细胞的培养基和培养方法
JPWO2023085369A1 (https=) 2021-11-11 2023-05-19

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105757A2 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
CA2556589A1 (en) 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
JP4652112B2 (ja) 2005-04-26 2011-03-16 富士フイルム株式会社 投射型表示装置
AU2008220104B2 (en) 2007-02-28 2012-09-27 Asahi Kasei Pharma Corporation Sulfonamide derivative
JP2011530518A (ja) 2008-08-05 2011-12-22 アボット・ラボラトリーズ タンパク質キナーゼの阻害剤として有用な化合物
US8957093B2 (en) 2011-06-06 2015-02-17 The Scripps Research Institute N-biphenylmethylindole modulators of PPARG
RS62867B1 (sr) * 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
ES2774923T3 (es) * 2014-04-28 2020-07-23 China Resources Pharmaceutical Holdings Company Ltd Derivados de isoquinolinsulfonilo como inhibidores de RHO quinasa
US9902702B2 (en) * 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
US9687483B2 (en) 2015-01-26 2017-06-27 BioAxone BioSciences, Inc. Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors
EP4509138A3 (en) 2016-12-21 2025-04-23 BioAxone BioSciences, Inc. Rho kinase inhibitor ba-1049 (r) and active metabolites thereof

Similar Documents

Publication Publication Date Title
JP2020502248A5 (https=)
JP2017514910A5 (https=)
FI3558314T3 (fi) Rho-kinaasin estäjä ba-1049 (r) ja sen aktiivisia aineenvaihduntatuotteita
JP2018024670A5 (https=)
MA49402A (fr) Polynucléotides aadc pour le traitement de la maladie de parkinson
EP3471660A4 (en) MEDICAL DEVICE FOR THE TREATMENT OF VASCULATORS
JP2017506627A5 (https=)
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
EP2916742A4 (en) DYNAMIC AXIAL NAIL FOR THE INTRAMEDULLARY TREATMENT OF TUBE BONE FRACTURES
WO2017090039A3 (en) Pharmaceutical compositions comprising levodopa amide and uses thereof
BR112017015852A2 (pt) forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
EP3400930C0 (en) COMPOSICIÓN PARA SU USO EN EL TRATAMIENTO DE LESIONES EN LA MUCOSA MEDIANTE RESECCIÓN ENDOSCÓPICA
MA55917A (fr) Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
WO2017117070A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
EP3419981A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY
MX2020012336A (es) Formulacion farmaceutica.
WO2018071741A8 (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
JP2016540015A5 (https=)
WO2011133841A3 (en) Intravenous omega-3 fatty acid compositions & method of use
WO2016199076A3 (en) Polymorphic forms of afatinib free base and afatinib dimaleate
TN2015000356A1 (en) Bicyclic compounds
JP2018145180A5 (https=)
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease